Literature DB >> 10618725

Stress-induced aberrant splicing of TSG101: association to high tumor grade and p53 status in breast cancers.

E Turpin1, B Dalle, A de Roquancourt, L F Plassa, M Marty, A Janin, Y Beuzard, H de Thé.   

Abstract

The TSG101 gene, identified through insertional mutagenesis, is localized in a region that exhibits LOH in human cancers, suggesting that TSG101 might be a tumor suppressor gene. Numerous studies have then shown the presence of abnormal transcripts in various tumors which appear to result from aberrant splicing of the gene, rather than from intragenic deletions. Moreover, many studies demonstrated that these aberrantly spliced transcripts were not found in matched normal tissues. We have analysed TSG101 transcripts in 85 breast cancer samples and found that abnormal splicing of the gene is tightly correlated with tumor grade and p53 mutation. In addition, stress induced the appearance of these abnormal transcripts in primary lymphocytes. Hence, TSG101 splicing defects, while unrelated to the oncogenic process per se, could reflect the cellular environment of the tumor cells. The proposed role of stress and hypoxia to select p53 mutant cells could account for the tight association with p53 status.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10618725     DOI: 10.1038/sj.onc.1203196

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues.

Authors:  Kay-Uwe Wagner; Andrea Krempler; Yongyue Qi; KyungRan Park; MaLinda D Henry; Aleata A Triplett; Gregory Riedlinger; Edmund B Rucker III; Lothar Hennighausen
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 2.  Hedgehog pathway and GLI1 isoforms in human cancer.

Authors:  Richard L Carpenter; Hui-Wen Lo
Journal:  Discov Med       Date:  2012-02       Impact factor: 2.970

3.  Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer.

Authors:  Earl Gillespie; Susan E Leeman; Luisa A Watts; Jennifer A Coukos; Michael J O'Brien; Sandra R Cerda; Francis A Farraye; Arthur F Stucchi; James M Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-03       Impact factor: 11.205

4.  A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.

Authors:  L Li; J Liao; J Ruland; T W Mak; S N Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 5.  Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors.

Authors:  Meike Körner; Laurence J Miller
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

6.  Transposable elements in disease-associated cryptic exons.

Authors:  Igor Vorechovsky
Journal:  Hum Genet       Date:  2009-10-10       Impact factor: 4.132

7.  Stress-induced expression of a novel variant of human fumarate hydratase (FH).

Authors:  Heli J Lehtonen; Sanna K Ylisaukko-Oja; Maija Kiuru; Auli Karhu; Rainer Lehtonen; Sakari Vanharanta; Anu Jalanko; Lauri A Aaltonen; Virpi Launonen
Journal:  Gene Expr       Date:  2007

8.  The WSB1 gene is involved in pancreatic cancer progression.

Authors:  Cendrine Archange; Jonathan Nowak; Stéphane Garcia; Vincent Moutardier; Ezequiel Luis Calvo; Jean-Charles Dagorn; Juan Lucio Iovanna
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

9.  Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.

Authors:  M Varna; H Soliman; J-P Feugeas; E Turpin; D Chapelin; L Legrès; L-F Plassa; A de Roquancourt; M Espié; J-L Misset; A Janin; H de Thé; P Bertheau
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

10.  Gene network screening of bladder cancer via modular analysis.

Authors:  Xiaodong Li; Ye Wu; Ye Yuan
Journal:  Transl Cancer Res       Date:  2021-02       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.